Researchers predicted the likelihood of achieving target T-scores in postmenopausal women with osteoporosis who received denosumab therapy for 10 years.

Amandine Miquel says last week's victory over Brighton is the "closest" her Leicester side have come to playing the way she ...

A new study has found that taking five grams of a creatine supplement daily, which is the upper limit of the recommended ...

Phase III (3 years; and 2-year follow-up) 401 premenopausal women with hormone-responsive breast cancer undergoing treatment ZA 4 mg iv. every 6 months Observational group LS BMD no change vs ↓ ...

On Monday, Edgewise Therapeutics, Inc., (NASDAQ:EWTX) revealed topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy (BMD), is a genetic ...

Would you like to become a test subject for medical studies? Here is everything you need to know about paid clinical trials ...

RXRX's CDK7 inhibitor REC-617 has demonstrated activity, but additional data from the ELUCIDATE trial in various solid tumors ...

The Cambridge-based biotech's experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, ...

Wave Life Sciences’ experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, setting the ...

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle ...